Compare Seagate Technology Holdings PLC (STX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Seagate Technology Holdings PLC vs State Street SPDR S&P Biotech ETF — how do they compare? Seagate Technology Holdings PLC trades at $783 (market cap $176.19B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Seagate Technology Holdings PLC is far larger — about 17.4× State Street SPDR S&P Biotech ETF's market cap, and Seagate Technology Holdings PLC pays a 0.38% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Seagate Technology Holdings PLC for 41 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| STX | XBI | |
|---|---|---|
Market Cap | $176.19B | $10.11B |
Volume | 5,061,875 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $1.09K | $169.55 |
52-Week Low | $211.63 | $104.99 |
Typical Hold Time | 41 Days | 38 Days |
Enterprise Value | $178.34B | — |
Dividend Yield | 0.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Seagate Technology (STX) trades at $774.83, down 4.03% amid concerns about increased competition from Toshiba's planned HDD production expansion. The stock shows strong fundamentals with Q2 2026 EPS beating expectations at $5.71 vs. $5.10 estimate, and robust profitability metrics including 26.11% net margin and 371.53% ROE. Technical indicators signal bearish momentum with the price below key resistance levels, while analyst consensus remains positive with 53.85% buy ratings and $1,130 price target.
Despite near-term competitive pressures, Seagate maintains strong positioning in AI storage markets with projected 2026 revenue growth to $12.2B. The primary risk involves Toshiba's capacity expansion potentially eroding pricing power. Current valuation multiples appear elevated (P/E 55.74, P/S 14.55) but are supported by exceptional profitability and AI-driven demand outlook.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite an oversold RSI reading. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive news flow around biotech catalysts. Recent articles highlight XBI's biotech focus versus broader healthcare ETFs, with expense ratio comparisons and volatility considerations.
The outlook remains cautious due to technical weakness and high volatility, though sector-specific catalysts like cancer vaccine developments and M&A activity provide potential upside. Key risks include sector volatility, regulatory uncertainty, and competitive ETF offerings with lower fees.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Seagate Technology Holdings PLC
Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
